CURRENT STATUS

The T1D cure has crossed from theory into human proof. Teplizumab (Tzield) is FDA-approved and delays clinical onset by a median of ~2 years in at-risk relatives. Vertex's stem cell-derived islets (zimislecel / VX-880) have produced insulin independence in the majority of fully dosed trial participants at one year — a functional cure in early patients — at the cost of chronic immunosuppression. An encapsulated, immunosuppression-free version (VX-264) and gene-edited "hypoimmune" islets are in earlier trials, while automated insulin-delivery systems already deliver near-normal glucose control today.

KEY BREAKTHROUGHS

Teplizumab (Tzield) — first drug to delay T1D onset, FDA-approved 2022

Vertex VX-880 stem cell-derived islets — patients achieving insulin independence in trials

CRISPR-edited hypoimmune stem cells evading rejection without immunosuppression

AI-designed closed-loop artificial pancreas systems achieving near-normal glucose control

AI-COMPRESSED PIPELINE

AI TOOLS ACCELERATING CURES

Immune Profiling AIBeta Cell Differentiation OptimizationAutoimmune Prediction ModelsSmart Insulin Delivery

KEY ORGANIZATIONS

Vertex PharmaceuticalsSana BiotechnologyProvention BioNovo NordiskJDRF

KEY CLINICAL TRIALS

Zimislecel (VX-880) — Stem Cell-Derived Islets for T1D (Phase 1/2/3)

View

Vertex Pharmaceuticals

A pivotal trial of zimislecel — fully differentiated islet cells made from stem cells and infused into the liver to restore the body’s own insulin production. In reported data, 10 of 12 fully dosed participants became insulin-independent at one year and all were free of severe hypoglycemic events — a functional cure in early patients. Requires chronic immunosuppression.

👥 ~50 adults with T1D and impaired hypoglycemia awareness📍 US, Canada, Europe — multicenter

TIMELINE ESTIMATE

Functional cure (stem cell islets): 3–5 years to broad availability. Full immune reset: 5–8 years.

EXPLORE FULL CURE PROTOCOL